To inhibit pancreatic secretions, which pharmacologic agent would you anticipate administering to a patient with acute pancreatitis?
A. Nitroglycerin
B. Somatostatin
C. Pancrelipase
D. Pepcid
Correct Answer: B. Somatostatin
Somatostatin, a treatment for acute pancreatitis, inhibits the release of pancreatic enzymes. Somatostatin produces predominantly neuroendocrine inhibitory effects across multiple systems. It is known to inhibit GI, endocrine, exocrine, pancreatic, and pituitary secretions, as well as modify neurotransmission and memory formation in the CNS.
Option A: Nitroglycerin is a vasodilator and does not affect pancreatic secretions. Nitroglycerin is a vasodilatory drug used primarily to provide relief from anginal chest pain. It is currently FDA approved for the acute relief of an attack or acute prophylaxis of angina pectoris secondary to coronary artery disease.
Option C: Pancrelipase is an enzyme that aids in the digestion and absorption of fats and proteins. Pancrelipase refers to a class of medications designed to treat malabsorption and abdominal pain secondary to exocrine pancreatic insufficiency. These agents serve as exogenous versions of digestive hormones and enzymes required for normal digestion and are ingested with meals to improve digestion, absorption, and abdominal pain frequently seen in chronic pancreatitis and exocrine pancreatic insufficiency.
Option D: Pepcid is an H2 blocker and is used to decrease gastric motility. H2 receptor blockers, or H2 receptor antagonists (H2RAs), are a class of gastric acid-suppressing agents frequently used in various gastric conditions. They are FDA-approved for short-term use in treating uncomplicated gastroesophageal reflux disease (GERD), gastric or duodenal ulcers, gastric hypersecretion, and mild to infrequent heartburn or indigestion.
No comments:
Post a Comment